SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
NCT04521309
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
BIOLOGICAL:
SARS-CoV-2 antibody based IVIG therapy
Sponsor
Dow University of Health Sciences
Collaborators
[object Object]